FIT screening

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers. The good news is that CRC incidence and mortality can be reduced significantly if detected early enough.

Faecal immunochemical tests (FIT) are non-invasive and can detect blood in stool invisible to the naked eye. Due to its simplicity, FIT is currently considered the best non-invasive test for CRC screening.

Invest a little time in your own health by taking the FIT to prevent or detect colon cancer early on.
For further information, please visit our ‘FIT for screening’ website



Please select your country. This will keep you up to date with your country-specific information.

OncoBEAM in lung cancer

  • Quick. Whenever. Just blood.
  • Highly sensitive liquid biopsy
  • Reliable detection of EGFR mutations


  • All
  • Brochure

OncoBEAM in lung cancer

Clinical significance of EGFR mutations in non-small cell lung cancer

EGFR mutations play an important role for therapy selection in non-small cell lung cancer (NSCLC) since they can lead to either resistance or sensitisation towards the different lines of anti-EGFR therapy. Therefore, testing for EGFR mutations is recommended to select patients likely to benefit from EGFR tyrosine kinase inhibition (TKI) therapy.3,4 For first-generation TKI the presence of sensitising EGFR is required. Of special interest are mutations that are associated with TKI resistance (EGFR T790M or C797S). Their assessment during therapy or at disease progression can provide valuable information about the patient’s response to the selected therapy.

Clinical studies comparing liquid and tissue biopsies have shown results equivalent to those of patients with T790M-positive tissue-based tumour results, suggesting that plasma genotyping may be considered instead of tissue biopsy to detect the EGFR T790M mutation.5 However, if the plasma biopsy is negative, a tissue biopsy is recommended, if feasible.5

Sysmex Inostics’ OncoBEAM liquid biopsy is an established technology for the detection of mutations based on cell-free DNA isolated from plasma. Additionally, its high sensitivity to detect EGFR mutations has been demonstrated in several clinical studies.1,2,5

Available products

Detection of 36 EGFR mutations in the human EGFR oncogene exons 18, 19, 20 and 21 (incl. T790M and C797S) using DNA extracted from 2 mL of plasma.

*For research use only. Any in vitro diagnostics purpose has not been established by the manufacturer.

OncoBEAM in colorectal cancer


The OncoBEAM advantage

The OncoBEAM advantage

1. High concordance with tissue
OncoBEAM EGFR demonstrated a high overall percent agreement in several clinical studies

2. Safe and convenient
Minimally invasive, low risk

3. Accurate information
Blood sample evaluation represents patient's current mutational status; information of tumour dynamics in real time (6)

4. No selection bias
Evaluate primary tumour and metastases from one sample

5. Ability to monitor
Allows multiple measurements to assess drug response and resistance (1,2)

Video: OncoBEAM Technology

Video: OncoBEAM Technology

Video: The oncologist’s experience

Video: The oncologist’s experience

Video: The patient’s experience with OncoBEAM

Video: The patient’s experience with OncoBEAM



  1. Taus A et al. (2018): Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma. Clinical Lung Cancer [Epub ahead of print]
  2. Yu H et al. (2017): A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clin Cancer Res 23(24):7467-7473.
  3. NCCN Clinical Practice Guidelines in Oncology™: Colon Cancer. National Comprehensive Cancer Network. V2.2016
  4. Novello S, Barlesi F, Califano R et al. (2016): Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl 5): v1–v27
  5. Oxnard GR et al. (2016): Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 34(28) : 3375 – 3382.
  6. Tabernero J et al. (2015): Analysis of Circulating DNA and Protein Biomarkers to Predict the Clinical Activity of Regorafenib and Assess Prognosis in Patients with Metastatic Colorectal Cancer: A Retrospective, Exploratory Analysis of the CORRECT Trial. The Lancet Oncology 16(8):937 – 948.
Sysmex Inostics Technologies & Services

Sysmex Inostics Technologies & Services

Want to know more about Sysmex Inostics offers?



Sysmex Europe GmbH

+49 (40) 527 26 0
+49 (40) 527 26 100
Bornbarch 1
22848 Norderstedt

Create Pdf
Enjoy our Media Centre
  • All
  • Documents
  • Podcast
  • Images
  • Videos
See our collection
Company movie